New investigational drug for patients with non-small cell lung cancer

Trial ID:
IRB-24-8472
Aditya R Sarvaria, MD

Inclusion Criteria

Patients must:

  • Be 18 years of age or older.
    Have a confirmed diagnosis of advanced and/or metastatic non-squamous NSCLC.
    Have documented HER2 mutation in the TKD.
    Have the presence of at least one measurable lesion
    Be eligible for standard of care treatment
    Have ECOG 0 or 1.
    Have adequate organ function based on laboratory values.

Exclusion Criteria

Patients must not:

  • Have tumors with targetable alterations with available approved therapy.
    Have presence or history of uncontrolled or symptomatic brain and subdural metastases, unless considered stable by the investigator and local therapy was completed.
    Have lung-specific clinically significant severe illness based on the investigator's assessment.
    Have radiotherapy within 4 weeks before randomization, except for palliative radiotherapy completed 2 weeks before randomization.
    Have major surgery performed within 4 weeks before randomization or planned within 6 months after screening.
    Have a history or presence of cardiovascular abnormalities.
    Have a history or presence of an uncontrolled gastrointestinal disorder.

Additional Info

All treatment and physician visits will take place at the Scripps Clinic Torrey Pines Geisel Pavilion or Scripps Prebys Cancer Center Mercy San Diego Campus.

For more information search NCT06151574 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • crsleadership@scrippshealth.org